Mar 21,2024

Newfoundland and Labrador expands access to continuous glucose monitoring program

Through its 2024 budget, Newfoundland and Labrador is expanding access to continuous glucose monitoring (CGM) for type 1 diabetes (T1D) patients. The program, which previously covered individuals under 18, will now include T1D patients up to age 25 in the provincial Insulin Pump Program and those pregnant with gestational diabetes. With $1.8 million in funding, the province aims to make CGM a permanent part of diabetes care, enhancing health outcomes and ease of management for more residents. JDRF Canada has praised the expansion, aligning with its ongoing advocacy for accessible diabetes technologies nationwide.

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Nov 01,2024

Insulet Announces Array of Activities to Support National Diabetes Awareness Month and World Diabetes Day in November

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, announced plans to recognize National Diabetes Awareness Month and World Diabetes Day with a series of activities in November. “People with diabetes must make dozens of decisions every day to manage their condition, which can be incredibly stressful, overwhelming at times, and get in the way of enjoying life. This impact often extends to family members and caregivers, a burden the general public largely underappreciates,” said Jim Hollingshead, President and Chief Executive Officer, who noted that an estimated 500 to 600 million adults are living with diabetes, which is forecasted to grow to more than 640 million by 2030. “At Insulet, where many of us have personal connections to diabetes, we all get to do something special, improving lives through our important work.”

View Analyst & Ambassador Comments
Go to original news
Feb 27,2024

Ensuring Canadians living with diabetes have access to the treatments and devices they need in Canada’s national pharmacare program

JDRF Canada is eagerly anticipating the upcoming national pharmacare program announcement, which is expected to cover essential diabetes medications, including insulin, as well as advanced diabetes devices like continuous glucose monitors (CGMs) and insulin pumps. This inclusion would honor Canada’s historic legacy in diabetes care, tracing back to the discovery of insulin by Banting, Collip, and Best. JDRF emphasizes that insulin pumps and CGMs are vital for type 1 diabetes (T1D) management, offering improved glucose control, reduced complications, and enhanced quality of life. By including these in the national pharmacare program, Canada would promote equitable healthcare access and reduce long-term healthcare costs.

View Analyst & Ambassador Comments
Go to original news
May 30,2024

Economic Savings Model for Omada’s Cardiometabolic Programs

Using a Markov model, this study estimated the reduction of disease onset and associated cost savings for Omada’s cardiometabolic programs. Estimated gross savings in medical expenditures across the programs in 2022 dollars were $892 to $1,342 after 1 year, and cumulative estimated gross medical savings were $2,963 to $4,346 after 3 years and $5,221 to $7,756 after 5 years.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Nov 01,2024

CMS grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral™ renal denervation catheter

Medtronic has announced that its Symplicity Spyral™ renal denervation (RDN) catheter has received transitional pass-through (TPT) payment status from the Centers for Medicare & Medicaid Services (CMS). Starting January 1, 2025, this TPT approval will reduce cost barriers under Medicare's Hospital Outpatient Prospective Payment System, making the innovative RDN procedure more accessible for patients with uncontrolled high blood pressure. The minimally invasive Symplicity Spyral system uses radiofrequency energy to calm overactive nerves near the kidneys, helping to manage hypertension when medications and lifestyle changes fall short. This designation highlights Medtronic’s commitment to expanding hypertension treatment options, which are crucial as hypertension remains a leading cause of heart attack and stroke.

View Analyst & Ambassador Comments
Go to original news
Mar 27,2024

Ypsomed sells its pen needle and BGM business to MTD and invests in the expansion of its Solothurn site

Ypsomed has agreed to transfer its pen needle and blood glucose monitoring system businesses to Medical Technology and Devices S.p.A. (MTD) as it intensifies its focus on digital diabetes solutions, particularly the mylife Loop insulin pump. This transfer, expected to be finalized by summer 2024, will ensure continued supply of unique pen needle options globally, with Ypsomed supporting a smooth transition by manufacturing pen needles during the interim. The transaction allows Ypsomed to concentrate on expanding autoinjector production at its Solothurn site, investing over CHF 100 million in capacity growth and creating new jobs.

#bgm

View Analyst & Ambassador Comments
Go to original news
Oct 29,2024 TOP STORY

Terumo Blood and Cell Technologies advances the adoption of automated manufacturing to bring novel cell and gene therapies to more Latin American patients The company is starting in Brazil, Col...

Terumo Blood and Cell Technologies is expanding its automated manufacturing offerings for cell and gene therapy companies in Brazil, Colombia, and Mexico, aiming to enhance accessibility to these advanced treatments in Latin America. The company focuses on developing technologies that improve the efficiency of manufacturing processes, which can lower costs and increase the availability of life-saving therapies, particularly important in regions with significant reliance on government healthcare systems. As the cell and gene therapy market in Latin America is projected to grow significantly, Terumo BCT's automation solutions are positioned to support the scaling of these therapies to better meet patient needs.

View Analyst & Ambassador Comments
Go to original news
Oct 29,2024 TOP STORY

Omnipod® 5 App for iPhone® Now Fully Available in the United States

Insulet Corporation has announced the full market release of the Omnipod 5 App for iPhone, now available for free download on the Apple App Store. This app enables users to manage their Omnipod 5 Automated Insulin Delivery System directly from their iPhones, eliminating the need for a separate controller. Key features include the ability to bolus for meals, change Pods, and adjust settings, along with a Custom Foods function that simplifies carbohydrate counting by allowing users to input and save their favorite foods. The app is designed to enhance the user experience, providing real-time glucose information on the home screen and supporting improved diabetes management. Currently, the Omnipod 5 App is compatible with the Dexcom G6 Continuous Glucose Monitoring (CGM) System, with plans for compatibility with the Dexcom G7 expected in 2025.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 14,2024

NAMSA and TERUMO ANNOUNCE STRATEGIC OUTSOURCING PARTNERSHIP NAMSA’s clinical research, testing and consulting services will help accelerate the regulatory approval of TERUMO’s medical devic...

NAMSA and Terumo have announced a strategic outsourcing partnership aimed at expediting the regulatory approval and commercialization of Terumo’s medical products. This collaboration will provide Terumo with immediate access to NAMSA's clinical experts and regulatory services, facilitating the development of innovative medical solutions across various fields, including diabetes care and vascular interventions. The partnership seeks to address the evolving regulatory landscape and enhance the efficiency of bringing new medical technologies to market, ultimately benefiting patients globally.

COLLABORATION PARTNERSHIP

#product & service

View Analyst & Ambassador Comments
Go to original news
Oct 29,2024

Injection Pen Market Set to Surge, Valued at USD 40.6 Billion in 2023, Projected to Reach USD 73.8 Billion by 2032

The global injection pen market, valued at $40.6 billion in 2023, is expected to reach $73.8 billion by 2032, driven by the growing demand for easy-to-use self-injection devices amid rising diabetes cases. Injection pens are increasingly favored over traditional syringes for their convenience and precise dosing, enhancing diabetes and chronic disease management.

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES